Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SHOP APOTHEKE EUROPE N.V.

(SAE)
  Report
Delayed Xetra  -  11:44 2022-12-09 am EST
45.35 EUR    0.00%
12/09SHOP APOTHEKE EUROPE NV : Baader Bank remains its Buy rating
MD
12/09SHOP APOTHEKE EUROPE NV : Receives a Buy rating from Warburg Research
MD
12/01SHOP APOTHEKE EUROPE NV : Hauck & Aufhauser reiterates its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE.

10/05/2022 | 01:02am EST

EQS-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): 9 Month figures/Preliminary Results
SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE.

05.10.2022 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE.

  • Non-Rx sales growth 22% in Q3 (9M 18%).
  • Total sales growth 20% to EUR 285 million in Q3 (9M 14% to EUR 877M).
  • Customer Net Promoter Score (NPS) again at record level well above 70.
  • Active customer base grew 0.2 million in Q3 to 8.9 million (YTD increase 1 million).
  • Positive adj. EBITDA margin expected for Q3.
  • Adoption of eRx in Germany is progressing steadily.

Sevenum, the Netherlands, 5 October 2022. According to preliminary figures, SHOP APOTHEKE EUROPE’s non-Rx sales, currently comprising the majority of the business and accounting for around 90% of total sales, increased by 22% year over year in Q3 2022 to 252M. Total sales increased by 20% year over year to EUR 285M, with Rx sales at EUR 33 million (+4% year over year). The active customer base continued to grow – up 0.2 million in Q3 and 1 million YTD to 8.9 million at the end of September; this is 1.5 million higher compared to September last year. The measure of customer satisfaction NPS (net promoter score) was again well above 70. SHOP APOTHEKE EUROPE achieved another quarter of strong performance in the logistic and pharmacy processes at Sevenum. In Italy, a significant improvement of the NPS was achieved after the opening of SHOP APOTHEKE EUROPE’s new distribution centre in Milan this summer, shortening delivery times.

SHOP APOTHEKE EUROPE’s CEO, Stefan Feltens, comments: “We had another very successful quarter, gaining market share in each of our seven countries. This achievement was the result of our focus on customer needs and excellent execution. Simultaneously, the adoption of eRx in Germany rose; the number of e-scripts doubled from 70k in both July and August to more than 140k in September.”

CFO, Jasper Eenhorst, adds: “We balanced growth, cost savings, and the bottom line. While we successfully continued to grow fast, we achieved a notable quarter over quarter increase in profitability. We now expect a positive adjusted EBITDA for the total group in Q3.”

At the start of the year, the Group provided guidance for 15% to 25% sales growth for the ongoing non-Rx business for full-year 2022, and has constantly delivered on this guidance. In Q3, non-Rx sales expanded by 22% year over year, with 21% growth in the DACH segment (Germany, Austria and Switzerland), and 25% in the International segment (Belgium, the Netherlands, France and Italy).

Sales in DACH increased from EUR 189 million in Q3 2021 to EUR 224 million in Q3 2022, with Rx sales in Germany in Q3 at EUR 33 million (Q3 2021: EUR 32M). In International, sales rose by 25% from EUR 48 million last year to EUR 61M. Total Group sales increased by 20% to EUR 285 million in Q3 (Q3 2021: EUR 238M). Year-to-date (9M), total sales grew 14% to EUR 877 million (9M 2021: EUR 772M).

On 1 September, the roll-out of e-prescriptions (eRx) started in Westfalen-Lippe. Following the test phase that ended successfully this summer with all criteria met by mid-July, the roll-out is a significant next step in the countrywide adoption of electronic prescriptions in Germany. In Q1, the average number of daily electronic prescriptions across Germany was around 70, in Q2 around 400, and in the last week of September more than 6,000.

The Management Board of SHOP APOTHEKE EUROPE reiterates its guidance for the ongoing business to grow non-Rx sales by 15% to 25% in the full year 2022, and to achieve an adjusted EBITDA margin in the range of -1.5% to 1.5%.

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE N.V. will release the Interim Report for Q3 2022 on 31 October 2022.

 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of Europe’s leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, 8.9 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services. In preparation for the full introduction of the electronic prescriptions in Germany, the company is continuously expanding in the area of digital health services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.



05.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: Investor.Relations@shop-apotheke.com
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1456721

 
End of News EQS News Service

1456721  05.10.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1456721&application_name=news&site_id=zonebourse_sftp

ę EQS 2022
All news about SHOP APOTHEKE EUROPE N.V.
12/09SHOP APOTHEKE EUROPE NV : Baader Bank remains its Buy rating
MD
12/09SHOP APOTHEKE EUROPE NV : Receives a Buy rating from Warburg Res..
MD
12/01SHOP APOTHEKE EUROPE NV : Hauck & Aufhauser reiterates its Buy r..
MD
11/17Shop Apotheke Europe N : Halfjaarlijkse financiële verslaggeving
PU
11/15SHOP APOTHEKE EUROPE NV : Deutsche Bank gives a Buy rating
MD
11/10SHOP APOTHEKE EUROPE NV : Barclays gives a Buy rating
MD
11/10At The Vision 2045 Summit Alongside : CEO Stefan Feltens presents SHOP APOTHEKE EUROPE's ..
EQ
11/07SHOP APOTHEKE EUROPE NV : Credit Suisse reiterates its Buy ratin..
MD
11/07Shop Apotheke Europe N : Transkript Earnings Call Q3 2022 (Englisch)
PU
11/04SHOP APOTHEKE EUROPE NV : Hauck & Aufhauser takes a positive vie..
MD
More news
Analyst Recommendations on SHOP APOTHEKE EUROPE N.V.
More recommendations
Financials
Sales 2022 1 212 M 1 277 M 1 277 M
Net income 2022 -68,4 M -72,1 M -72,1 M
Net Debt 2022 72,8 M 76,8 M 76,8 M
P/E ratio 2022 -12,0x
Yield 2022 -
Capitalization 821 M 865 M 865 M
EV / Sales 2022 0,74x
EV / Sales 2023 0,66x
Nbr of Employees 1 584
Free-Float 99,4%
Chart SHOP APOTHEKE EUROPE N.V.
Duration : Period :
Shop Apotheke Europe N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHOP APOTHEKE EUROPE N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 45,35 €
Average target price 86,43 €
Spread / Average Target 90,6%
EPS Revisions
Managers and Directors
Stefan Feltens Chief Executive Officer
Jasper Eenhorst Chief Financial Officer
Bj÷rn H. S÷der Chairman-Supervisory Board
Marc Fischer Chief Information Officer
Theresa Holler Chief Operating Officer